NN344

DB05115

small molecule investigational

Deskripsi

NN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection. NN344 has a very flat and predictable action profile. The product is intended for basal insulin treatment of diabetes mellitus.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

925 Data
Liraglutide Liraglutide may increase the hypoglycemic activities of NN344.
Metreleptin Metreleptin may increase the hypoglycemic activities of NN344.
Pegvisomant The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with NN344.
Pioglitazone The risk or severity of adverse effects can be increased when Pioglitazone is combined with NN344.
Pramlintide Pramlintide may increase the hypoglycemic activities of NN344.
Rosiglitazone The risk or severity of congestive heart failure can be increased when NN344 is combined with Rosiglitazone.
Lipoic acid The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with NN344.
Edetic acid Edetic acid may increase the hypoglycemic activities of NN344.
Esmolol Esmolol may increase the hypoglycemic activities of NN344.
Landiolol Landiolol may increase the hypoglycemic activities of NN344.
Moxifloxacin The therapeutic efficacy of NN344 can be increased when used in combination with Moxifloxacin.
Grepafloxacin The therapeutic efficacy of NN344 can be increased when used in combination with Grepafloxacin.
Enoxacin The therapeutic efficacy of NN344 can be increased when used in combination with Enoxacin.
Pefloxacin The therapeutic efficacy of NN344 can be increased when used in combination with Pefloxacin.
Ciprofloxacin The therapeutic efficacy of NN344 can be increased when used in combination with Ciprofloxacin.
Trovafloxacin The therapeutic efficacy of NN344 can be increased when used in combination with Trovafloxacin.
Nalidixic acid The therapeutic efficacy of NN344 can be increased when used in combination with Nalidixic acid.
Rosoxacin The therapeutic efficacy of NN344 can be increased when used in combination with Rosoxacin.
Cinoxacin The therapeutic efficacy of NN344 can be increased when used in combination with Cinoxacin.
Lomefloxacin The therapeutic efficacy of NN344 can be increased when used in combination with Lomefloxacin.
Gatifloxacin The therapeutic efficacy of NN344 can be increased when used in combination with Gatifloxacin.
Norfloxacin The therapeutic efficacy of NN344 can be increased when used in combination with Norfloxacin.
Levofloxacin The therapeutic efficacy of NN344 can be increased when used in combination with Levofloxacin.
Gemifloxacin The therapeutic efficacy of NN344 can be increased when used in combination with Gemifloxacin.
Ofloxacin The therapeutic efficacy of NN344 can be increased when used in combination with Ofloxacin.
Sparfloxacin The therapeutic efficacy of NN344 can be increased when used in combination with Sparfloxacin.
Temafloxacin The therapeutic efficacy of NN344 can be increased when used in combination with Temafloxacin.
Fleroxacin The therapeutic efficacy of NN344 can be increased when used in combination with Fleroxacin.
Technetium Tc-99m ciprofloxacin The therapeutic efficacy of NN344 can be increased when used in combination with Technetium Tc-99m ciprofloxacin.
Garenoxacin The therapeutic efficacy of NN344 can be increased when used in combination with Garenoxacin.
Nemonoxacin The therapeutic efficacy of NN344 can be increased when used in combination with Nemonoxacin.
Flumequine The therapeutic efficacy of NN344 can be increased when used in combination with Flumequine.
Enrofloxacin The therapeutic efficacy of NN344 can be increased when used in combination with Enrofloxacin.
Orbifloxacin The therapeutic efficacy of NN344 can be increased when used in combination with Orbifloxacin.
Sarafloxacin The therapeutic efficacy of NN344 can be increased when used in combination with Sarafloxacin.
Difloxacin The therapeutic efficacy of NN344 can be increased when used in combination with Difloxacin.
Pazufloxacin The therapeutic efficacy of NN344 can be increased when used in combination with Pazufloxacin.
Prulifloxacin The therapeutic efficacy of NN344 can be increased when used in combination with Prulifloxacin.
Delafloxacin The therapeutic efficacy of NN344 can be increased when used in combination with Delafloxacin.
Sitafloxacin The therapeutic efficacy of NN344 can be increased when used in combination with Sitafloxacin.
Oxolinic acid The therapeutic efficacy of NN344 can be increased when used in combination with Oxolinic acid.
Rufloxacin The therapeutic efficacy of NN344 can be increased when used in combination with Rufloxacin.
Pipemidic acid The therapeutic efficacy of NN344 can be increased when used in combination with Pipemidic acid.
Methyclothiazide The risk or severity of hypoglycemia can be increased when Methyclothiazide is combined with NN344.
Chlorthalidone The risk or severity of hypoglycemia can be increased when Chlorthalidone is combined with NN344.
Bendroflumethiazide The risk or severity of hypoglycemia can be increased when Bendroflumethiazide is combined with NN344.
Metolazone The risk or severity of hypoglycemia can be increased when Metolazone is combined with NN344.
Benzthiazide The risk or severity of hypoglycemia can be increased when Benzthiazide is combined with NN344.
Hydroflumethiazide The risk or severity of hypoglycemia can be increased when Hydroflumethiazide is combined with NN344.
Indapamide The risk or severity of hypoglycemia can be increased when Indapamide is combined with NN344.
Chlorothiazide The risk or severity of hypoglycemia can be increased when Chlorothiazide is combined with NN344.
Hydrochlorothiazide The risk or severity of hypoglycemia can be increased when Hydrochlorothiazide is combined with NN344.
Trichlormethiazide The risk or severity of hypoglycemia can be increased when Trichlormethiazide is combined with NN344.
Polythiazide The risk or severity of hypoglycemia can be increased when Polythiazide is combined with NN344.
Quinethazone The risk or severity of hypoglycemia can be increased when Quinethazone is combined with NN344.
Cyclopenthiazide The risk or severity of hypoglycemia can be increased when Cyclopenthiazide is combined with NN344.
Epitizide The therapeutic efficacy of NN344 can be decreased when used in combination with Epitizide.
Protriptyline Protriptyline may decrease the hypoglycemic activities of NN344.
Amoxapine Amoxapine may decrease the hypoglycemic activities of NN344.
Trimipramine Trimipramine may decrease the hypoglycemic activities of NN344.
Amineptine Amineptine may decrease the hypoglycemic activities of NN344.
Dimetacrine Dimetacrine may decrease the hypoglycemic activities of NN344.
Butriptyline Butriptyline may decrease the hypoglycemic activities of NN344.
Dosulepin Dosulepin may decrease the hypoglycemic activities of NN344.
Tianeptine Tianeptine may decrease the hypoglycemic activities of NN344.
Oxaprotiline Oxaprotiline may decrease the hypoglycemic activities of NN344.
Opipramol Opipramol may decrease the hypoglycemic activities of NN344.
Amitriptylinoxide Amitriptylinoxide may decrease the hypoglycemic activities of NN344.
Dibenzepin Dibenzepin may decrease the hypoglycemic activities of NN344.
Quinupramine Quinupramine may decrease the hypoglycemic activities of NN344.
Melitracen Melitracen may decrease the hypoglycemic activities of NN344.
Lofepramine Lofepramine may decrease the hypoglycemic activities of NN344.
Iprindole Iprindole may decrease the hypoglycemic activities of NN344.
Imipramine oxide Imipramine oxide may decrease the hypoglycemic activities of NN344.
Nortriptyline Nortriptyline may decrease the hypoglycemic activities of NN344.
Desipramine Desipramine may decrease the hypoglycemic activities of NN344.
Dapagliflozin The risk or severity of hypoglycemia can be increased when NN344 is combined with Dapagliflozin.
Canagliflozin The risk or severity of hypoglycemia can be increased when NN344 is combined with Canagliflozin.
Leuprolide The therapeutic efficacy of NN344 can be decreased when used in combination with Leuprolide.
Goserelin The therapeutic efficacy of NN344 can be decreased when used in combination with Goserelin.
Nelfinavir The therapeutic efficacy of NN344 can be decreased when used in combination with Nelfinavir.
Indinavir The therapeutic efficacy of NN344 can be decreased when used in combination with Indinavir.
Ziprasidone The therapeutic efficacy of NN344 can be decreased when used in combination with Ziprasidone.
Etonogestrel The therapeutic efficacy of NN344 can be decreased when used in combination with Etonogestrel.
Desogestrel The therapeutic efficacy of NN344 can be decreased when used in combination with Desogestrel.
Olanzapine The therapeutic efficacy of NN344 can be decreased when used in combination with Olanzapine.
Megestrol acetate The therapeutic efficacy of NN344 can be decreased when used in combination with Megestrol acetate.
Clozapine The therapeutic efficacy of NN344 can be decreased when used in combination with Clozapine.
Levonorgestrel The therapeutic efficacy of NN344 can be decreased when used in combination with Levonorgestrel.
Progesterone The therapeutic efficacy of NN344 can be decreased when used in combination with Progesterone.
Chlorpromazine The therapeutic efficacy of NN344 can be decreased when used in combination with Chlorpromazine.
Haloperidol The therapeutic efficacy of NN344 can be decreased when used in combination with Haloperidol.
Ritonavir The therapeutic efficacy of NN344 can be decreased when used in combination with Ritonavir.
Piperazine The therapeutic efficacy of NN344 can be decreased when used in combination with Piperazine.
Medroxyprogesterone acetate The therapeutic efficacy of NN344 can be decreased when used in combination with Medroxyprogesterone acetate.
Niacin The therapeutic efficacy of NN344 can be decreased when used in combination with Niacin.
Epinephrine The therapeutic efficacy of NN344 can be decreased when used in combination with Epinephrine.
Norethisterone The therapeutic efficacy of NN344 can be decreased when used in combination with Norethisterone.
Risperidone The therapeutic efficacy of NN344 can be decreased when used in combination with Risperidone.
Pentamidine The risk or severity of hypoglycemia can be increased when Pentamidine is combined with NN344.

Target Protein

Insulin receptor INSR

Referensi & Sumber

Artikel (PubMed)
  • PMID: 17391154
    Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T: Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 2007 May;9(3):290-9.
  • PMID: 16362452
    Jonassen I, Havelund S, Ribel U, Plum A, Loftager M, Hoeg-Jensen T, Volund A, Markussen J: Biochemical and physiological properties of a novel series of long-acting insulin analogs obtained by acylation with cholic acid derivatives. Pharm Res. 2006 Jan;23(1):49-55. Epub 2006 Dec 21.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul